Distinguished in Primary Biliary Cholangitis

Richard J. Aspinall

Portsmouth, ENG, GB 
Distinguished in Primary Biliary Cholangitis
Portsmouth, ENG, GB 
OverviewLocationsClinical Research

Overview

Richard Aspinall practices in Portsmouth, United Kingdom. Mr. Aspinall is rated as a Distinguished expert by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Liver Failure, Primary Biliary Cholangitis, Cholangitis, Cirrhosis, and Liver Transplant.

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 2 clinical trials in the study of Primary Biliary Cholangitis.

Gender
Male

Locations

Portsmouth, ENG, United Kingdom
Other Locations
Priory Street, Conventry, Coventry, ENG CV15FB, United Kingdom
Aberdeen, SCT AB158QH, United Kingdom
Cambridge, ENG, United Kingdom
Chelmsford, ENG, United Kingdom
Cranfield, ENG, United Kingdom
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

82 Total Publications

Implementation of a care bundle improves PBC management.
Implementation of a care bundle improves PBC management.
Journal: JHEP reports : innovation in hepatology
Published: December 08, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Aspinall's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile